Establishment Labs (NASDAQ:ESTA) Hits New 1-Year High - Time to Buy?

Key Points

• Establishment Labs shares reached a new 52-week high, trading as high as $97.59 and closing last at $95.11. Analysts maintain a “Moderate Buy” consensus, with seven Buy ratings, one Hold and one Sell, though the $90.43 consensus target is below the current price.
• The company’s latest quarter showed 44.7% year-over-year revenue growth to $59.88 million, exceeding estimates, but its adjusted loss of $0.45 per share was wider than expected. Analysts forecast a full-year loss of $1.07 per share.
• Institutional investors own approximately 72.91% of the stock, with several funds increasing or initiating positions, while a company director sold 105,000 shares worth about $7.9 million.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as $97.59 and last traded at $95.11, with a volume of 144133 shares traded. The stock had previously closed at $92.54.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ESTA. Weiss Ratings reiterated a "sell (e+)" rating on shares of Establishment Labs in a report on Wednesday, June 24th. Citigroup upped their target price on shares of Establishment Labs from $76.00 to $92.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 8th. BTIG Research reaffirmed a "buy" rating on shares of Establishment Labs in a report on Monday, July 13th. TD Cowen reiterated a "buy" rating on shares of Establishment Labs in a research report on Monday. Finally, Mizuho boosted their price target on Establishment Labs from $100.00 to $105.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 15th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $90.43.

Establishment Labs Stock Up 2.4%

The firm's fifty day simple moving average is $84.92 and its 200-day simple moving average is $73.57. The company has a market cap of $2.79 billion, a PE ratio of -63.62 and a beta of 1.06. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business had revenue of $59.88 million for the quarter, compared to analysts' expectations of $57.40 million. During the same period last year, the business earned ($0.70) earnings per share. The company's revenue for the quarter was up 44.7% on a year-over-year basis. As a group, equities research analysts expect that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business's stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares of the company's stock, valued at $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 9.99% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ESTA. Goldman Sachs Group Inc. boosted its stake in Establishment Labs by 117.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company's stock worth $59,145,000 after buying an additional 438,206 shares during the last quarter. Viking Global Investors LP purchased a new position in shares of Establishment Labs during the 2nd quarter worth about $14,669,000. Soleus Capital Management L.P. purchased a new position in shares of Establishment Labs during the 2nd quarter worth about $9,050,000. Summit Partners Public Asset Management LLC lifted its holdings in shares of Establishment Labs by 87.1% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company's stock worth $17,632,000 after acquiring an additional 200,255 shares during the period. Finally, Nantahala Capital Management LLC boosted its position in shares of Establishment Labs by 11.1% in the third quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company's stock worth $80,893,000 after acquiring an additional 197,962 shares during the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.